Hormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease
Abstract: Metabolic dysfunction-associated fatty liver disease (MAFLD) has reached epidemic proportions globally in parallel to the rising prevalence of obesity. Despite its significant burden, there is no approved pharmacotherapy specifically tailored for this disease. Many potential drug candidates for MAFLD have encountered setbacks in clinical trials, due to safety concerns or/and insufficient therapeutic efficacy. Nonetheless, several investigational drugs that mimic the actions of endogenous metabolic hormones, including thyroid hormone receptor β (THRβ) agonists, fibroblast growth factor 21 (FGF21) analogues, and glucagon-like peptide-1 receptor agonists (GLP-1RAs), showed promising therapeutic efficacy and excellent safety profiles. Among them, resmetirom, a liver-targeted THRβ-selective agonist, has met the primary outcomes in alleviation of metabolic dysfunction-associated steatohepatitis (MASH), the advanced form of MAFLD, and liver fibrosis in phase-3 clinical trials. These hormone-based pharmacotherapies not only exhibit varied degrees of therapeutic efficacy in mitigating hepatic steatosis, inflammation and fibrosis, but also improve metabolic profiles. Furthermore, these three hormonal agonists/analogues act in a complementary manner to exert their pharmacological effects, suggesting their combined therapies may yield synergistic therapeutic benefits. Further in-depth studies on the intricate interplay among these metabolic hormones are imperative for the development of more efficacious combination therapies, enabling precision management of MAFLD and its associated comorbidities.
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Hormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease ; volume:4 ; number:2 ; year:2024 ; pages:158-168 ; extent:011
Medical Review ; 4, Heft 2 (2024), 158-168 (gesamt 011)
- Creator
-
Chui, Zara Siu Wa
Xue, Yaqian
Xu, Aimin
- DOI
-
10.1515/mr-2024-0007
- URN
-
urn:nbn:de:101:1-2404261704504.111109663856
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chui, Zara Siu Wa
- Xue, Yaqian
- Xu, Aimin
Other Objects (12)
The relationship between follicle-stimulating hormone and metabolic dysfunction-associated fatty liver disease in men
Emerging pharmacotherapy for cancer patients with cognitive dysfunction
Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease
Metabolic dysfunction associated fatty liver disease in healthy weight individuals
Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD)
Metabolic effects of reduced growth hormone action in fatty liver disease
Associations of sex-related and thyroid-related hormones with risk of metabolic dysfunction-associated fatty liver disease in T2DM patients
Nuclear factor interleukin 3 and metabolic dysfunction-associated fatty liver disease development
Risk Scores for Metabolic Dysfunction-Associated Fatty Liver Disease in Pediatric Obesity
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research
Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives
The relationship between follicle-stimulating hormone and metabolic dysfunction-associated fatty liver disease in men
Emerging pharmacotherapy for cancer patients with cognitive dysfunction
Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease
Metabolic dysfunction associated fatty liver disease in healthy weight individuals
Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD)
Metabolic effects of reduced growth hormone action in fatty liver disease
Associations of sex-related and thyroid-related hormones with risk of metabolic dysfunction-associated fatty liver disease in T2DM patients
Nuclear factor interleukin 3 and metabolic dysfunction-associated fatty liver disease development
Risk Scores for Metabolic Dysfunction-Associated Fatty Liver Disease in Pediatric Obesity
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research
Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives
The relationship between follicle-stimulating hormone and metabolic dysfunction-associated fatty liver disease in men
Emerging pharmacotherapy for cancer patients with cognitive dysfunction
Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease
Metabolic dysfunction associated fatty liver disease in healthy weight individuals
Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD)
Metabolic effects of reduced growth hormone action in fatty liver disease
Associations of sex-related and thyroid-related hormones with risk of metabolic dysfunction-associated fatty liver disease in T2DM patients
Nuclear factor interleukin 3 and metabolic dysfunction-associated fatty liver disease development
Risk Scores for Metabolic Dysfunction-Associated Fatty Liver Disease in Pediatric Obesity
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research